Hexarelin: Benefits, Evidence, Dosing & Side Effects
Disclaimer: This article is for educational purposes only and should not be construed as medical advice. Hexarelin is not approved for therapeutic use in most jurisdictions, including the United States, where it exists in a regulatory gray area as a research peptide. Always consult a qualified healthcare provider before considering any peptide or compound, especially those with limited human safety data.
Overview
Hexarelin (also known as Examorelin) is a synthetic hexapeptide that belongs to a class of compounds called growth hormone secretagogues (GHS). It works by potently stimulating the body's natural production of growth hormone, triggering a cascade of metabolic and physiological effects that researchers have investigated for applications ranging from muscle health to cardiac protection.
Unlike some growth hormone-releasing compounds that mimic growth hormone-releasing hormone (GHRH), hexarelin operates through a distinct mechanism—activating the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus while simultaneously binding to CD36 scavenger receptors. This dual action provides both the growth hormone-stimulating benefits characteristic of GHS compounds and unique cardioprotective properties not seen with other secretagogues.
The compound has garnered scientific interest primarily for its potential anabolic, cardioprotective, and metabolic effects, though it remains a research chemical without regulatory approval for human therapeutic use in most regions. This article synthesizes current evidence on hexarelin's mechanisms, efficacy across multiple health domains, appropriate dosing, side effects, and safety considerations.
How It Works: Mechanism of Action
Hexarelin's effects stem from two primary mechanisms:
GHS Receptor Activation
Hexarelin acts as a potent agonist at the growth hormone secretagogue receptor 1a (GHSR-1a), also known as the ghrelin receptor. This activation occurs in both the pituitary gland and hypothalamus, triggering robust pulses of growth hormone release. Once released, growth hormone stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which drives downstream anabolic signaling and tissue repair processes.
CD36 Scavenger Receptor Binding
Distinct from other GHS compounds, hexarelin independently binds to CD36 scavenger receptors in cardiac and other tissues. This action contributes to anti-fibrotic, anti-ischemic, and anti-inflammatory effects that appear independent of the classical GHS pathway. This mechanism underlies much of hexarelin's emerging cardioprotective profile.
Together, these dual pathways position hexarelin as a multifunctional compound capable of stimulating systemic anabolic processes while simultaneously exerting localized protective effects in vulnerable tissues like the heart.
Evidence by Health Goal
Fat Loss
Evidence Tier: 2 — Limited mechanistic potential; no human RCTs demonstrating meaningful weight loss.
Hexarelin potently stimulates growth hormone release, which theoretically supports fat mobilization. However, real-world efficacy for fat loss in humans remains unproven.
In obese patients, the GH response to hexarelin was substantially blunted compared to lean controls—peaking at 18.2 ± 3.8 μg/L versus 58.1 ± 10.3 μg/L in controls (n=9 obese, observational study). Despite this reduced response, hexarelin still significantly elevated GH compared to GHRH alone, suggesting potential utility even in metabolically challenged populations.
Animal evidence is more promising: in a 12-day mouse study, hexarelin decreased both plasma and liver triglycerides and improved glucose and insulin tolerance in insulin-resistant mice, despite increased food intake. However, this translates poorly to human outcomes, where no randomized controlled trials have demonstrated clinically meaningful weight loss or fat mass reduction.
Muscle Growth
Evidence Tier: 2 — No human studies; animal models show potential via mitochondrial protection, not direct hypertrophy.
Hexarelin has not been directly tested for muscle hypertrophy or strength gains in humans. All evidence comes from animal models demonstrating indirect benefits to muscle health.
In rats with cisplatin-induced cachexia (chemotherapy-induced muscle wasting), hexarelin antagonized mitochondrial dysfunction by restoring key biogenesis markers—PGC-1α, NRF-1, and TFAM expression—and preserving mitochondrial mass in the tibialis anterior muscle. In insulin-resistant mice, hexarelin improved glucose tolerance and plasma/liver triglycerides, but total body weight did not increase despite elevated food intake, suggesting metabolic remodeling rather than hypertrophy.
Human efficacy for muscle growth remains unproven.
Injury Recovery
Evidence Tier: 2 — Consistent animal data; no human RCTs.
Hexarelin demonstrates consistent cardioprotective effects against ischemia-reperfusion injury in multiple rodent models, but lacks any robust human clinical trial evidence.
In aged rats (24 months old), hexarelin at 80 μg/kg injected twice daily for 21 days improved recovery of left ventricular developed pressure at reperfusion to 90% of preischemic values, compared to only 37% in controls (p<0.01). In isolated mouse cardiomyocytes, hexarelin at 1 nanoMolar concentration prevented ischemia-reperfusion-induced reduction in cell contraction and calcium dynamics through GHS receptor-dependent recovery of phosphorylated phospholamban.
These findings are compelling for cardiac protection but have not been replicated in human subjects.
Anti-Inflammation
Evidence Tier: 2 — Demonstrated in cardiac models; limited broader anti-inflammatory evidence in humans.
Hexarelin shows anti-inflammatory effects in cardiac injury models, reducing inflammatory cytokines. In a mouse myocardial infarction model, hexarelin (0.3 mg/kg/day for 21 days) reduced TNF-α and IL-1β levels and decreased troponin-I, indicating reduced cardiomyocyte injury (n=11, animal RCT). In another mouse ischemia-reperfusion model, hexarelin decreased TGF-β1 expression, interstitial collagen deposition, and myofibroblast differentiation (n=20, animal RCT).
Evidence for broad anti-inflammatory efficacy outside the cardiac context is limited to mechanistic studies.
Cognition
Evidence Tier: 1 — No human studies; neuroprotective properties in cells and isolated animal tissues only.
Hexarelin has not been studied for cognitive enhancement in humans. All evidence comes from cell and tissue-level mechanistic studies.
Hexarelin promoted survival of retinal ganglion cells in hamsters, with 74.6% survival at 100 μg/kg versus 51.2% in saline controls. In human neuroblastoma cells expressing SOD1-G93A mutation (an Alzheimer's-related pathology model), hexarelin protected against hydrogen peroxide-induced cytotoxicity by activating pro-survival pathways.
These findings suggest neuroprotective potential but provide no evidence of cognitive enhancement in living subjects.
Mood & Stress
Evidence Tier: 1 — No studies whatsoever on mood or stress outcomes.
Despite extensive documentation of hexarelin's hormonal effects, no published studies have examined mood or psychological stress. Hexarelin significantly increases ACTH and cortisol release in healthy volunteers (ACTH area under curve of 3,444±696 ng/L × 125 minutes; cortisol 45,844±2,925 nmol/L × 125 minutes), but no mood or stress outcomes were measured.
Hexarelin decreases slow-wave and stage 4 sleep while increasing cortisol, ACTH, and prolactin during sleep, but sleep architecture changes should not be conflated with mood assessment.
Longevity
Evidence Tier: 2 — GH stimulation confirmed; direct longevity benefits absent.
Hexarelin consistently stimulates growth hormone secretion in humans and animals, but no evidence demonstrates that this translates to meaningful lifespan extension or improved aging outcomes.
In elderly humans (n=16, age 66-81), hexarelin at 2.0 μg/kg induced a dose-dependent GH response (AUC 742.8 ± 157.9 μg/L/h), significantly lower than young controls but preserved when combined with arginine. In aged beagle dogs treated with hexarelin at 500 μg/kg/day for 16 weeks, urinary lysylpyridinoline (a bone resorption marker) decreased significantly, and muscle morphology improved in 3 of 6 dogs, though plasma IGF-1 remained unchanged.
No lifespan or aging outcome data exists.
Immune Support
Evidence Tier: 2 — Limited to one animal model; no human trials.
Hexarelin shows potential immunomodulatory effects in acute lung injury models. In mice with acute lung injury, hexarelin at 320 μg/kg reduced total immune cell recruitment in bronchoalveolar lavage at 24 hours and lower neutrophil recruitment compared to vehicle. Hexarelin-treated mice also showed significantly reduced pulmonary collagen deposition at day 14, suggesting reduced fibrotic immune response.
Human efficacy for immune support remains entirely unproven.
Energy & Fatigue
Evidence Tier: 2 — Plausible mechanisms in cell and animal models; no human trials.
Hexarelin shows theoretical support for energy metabolism through mitochondrial biogenesis activation. In 3T3-L1 adipocytes (fat cells), hexarelin treatment resulted in intracellular lipid depletion with increased expression of fatty acid mobilization genes (FATP, CPT-1, F1-ATPase) and thermogenic markers (PGC-1α, UCP-1), suggesting activation of fat-burning metabolism.
In rat skeletal muscle, hexarelin antagonized cisplatin-induced decreases in mitochondrial biogenesis markers (PGC-1α, NRF-1, TFAM), protecting against muscle wasting. However, no human trials have directly tested energy or fatigue outcomes.
Heart Health
Evidence Tier: 3 — Probable efficacy in humans based on small RCTs; limited by sample size and lack of replication.
Hexarelin demonstrates the most robust human evidence for cardiac benefits, though studies remain small and short-term.
In human coronary artery disease patients during bypass surgery, acute intravenous hexarelin at 2.0 µg/kg increased left ventricular ejection fraction (LVEF), cardiac index, and cardiac output—all p<0.001—within 10 minutes, with effects lasting up to 90 minutes (n=24, RCT). In another human study (n=7, RCT), acute hexarelin significantly increased LVEF from 64.0±1.5% to 70.7±3.0% (p<0.03) within 15-30 minutes, independent of growth hormone release.
These improvements suggest direct cardiac effects, though studies are limited by small sample sizes and acute dosing protocols.
Liver Health
Evidence Tier: 2 — Emerging promise in animal models; no human RCTs.
Hexarelin shows potential for improving liver health through lipid metabolism improvements. In nonobese insulin-resistant mice, twice-daily hexarelin injections at 200 μg/kg for 12 days reduced hepatic and plasma triglycerides while improving glucose and insulin tolerance.
In obese hyperphagic mice, hexarelin stimulated pulsatile GH secretion, reducing visceral fat mass and liver triglyceride content over 3-4 weeks. However, no human RCTs or clinical trials have tested efficacy in liver disease.
Hormonal Balance
Evidence Tier: 3 — Demonstrates hormonal effects in humans; limited by small acute studies rather than long-term efficacy trials.
Hexarelin powerfully stimulates growth hormone, prolactin, and cortisol release in a dose-dependent manner in humans. The GH dose-response curve plateaus at 140 mU/L with an ED50 (half-maximal effective dose) of 0.48±0.02 µg/kg (n=7, RCT). Prolactin shows a dose-response plateau at 180% rise from baseline with an ED50 of 0.39±0.02 µg/kg, while cortisol shows a step increase to approximately 40% at the 0.5 µg/kg dose.
When combined with GHRH, hexarelin produces synergistic GH responses exceeding the arithmetic sum of individual responses (p=0.001; n=6).
Most evidence comes from acute single-dose studies in small samples, limiting proof of sustained clinical benefit with long-term use.
Sexual Health
Evidence Tier: 2 — Consistent penile erection induction in male rats; no human trials.
Hexarelin analogues consistently induce penile erection in male rats through activation of central oxytocinergic neurons and nitric oxide pathways. EP 80661 (a hexarelin analogue) induced dose-dependent penile erection in male rats at 20-200 nanograms when injected into the paraventricular nucleus, with potency comparable to apomorphine, oxytocin, and NMDA.
Other hexarelin analogues (EP 60761 and EP 50885) increased spontaneous penile erections in rats at doses of 20-2000 nanograms, with EP 60761 active at just 20 nanograms, inducing erection in 70% of treated animals. No human clinical trials exist for this compound.
Athletic Performance
Evidence Tier: 1 — No human evidence; theoretical mechanisms only.
No human evidence exists for hexarelin and athletic performance. A mechanistic review notes that hexarelin may improve cardiac function post-infarction through GH secretion or cardiac GHS receptor activation, and theoretically GH may improve exercise performance through effects on contractility and peripheral resistance, but no controlled trials have tested athletic outcomes.